Acutus Medical (NASDAQ:AFIB – Get Free Report) is projected to release its results before the market opens on Thursday, March 12th. Analysts expect Acutus Medical to post earnings of ($0.19) per share and revenue of $12.40 million for the quarter.
Acutus Medical Price Performance
NASDAQ:AFIB opened at $0.00 on Wednesday. Acutus Medical has a 52 week low of $0.00 and a 52 week high of $0.05. The company has a market cap of $8,933.70, a P/E ratio of 0.00 and a beta of -1.27.
Acutus Medical Company Profile
Acutus Medical is a commercial-stage medical technology company specializing in the development and commercialization of advanced cardiac mapping systems designed to improve the diagnosis and treatment of complex cardiac arrhythmias. The company’s flagship product, AcQMap, integrates high-resolution ultrasound imaging with electrical mapping to deliver comprehensive three-dimensional visualizations of arrhythmic sources, aiding electrophysiologists in the targeted management of conditions such as atrial fibrillation.
The AcQMap system employs a noncontact, high-density mapping catheter alongside ultrasound-based anatomical reconstruction to enable rapid, global mapping of cardiac chambers.
Featured Stories
- Five stocks we like better than Acutus Medical
- The gold chart Wall Street is terrified of…
- What a Former CIA Agent Knows About the Coming Collapse
- Elon Musk already made me a “wealthy man”
- Unlocked: Elon Musk’s Next Big IPO
- 1,500 Banks Just Handed the Fed Your Bank Account
Receive News & Ratings for Acutus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acutus Medical and related companies with MarketBeat.com's FREE daily email newsletter.
